



บริษัท โรงงานเภสัชอุตสาหกรรม เจเอสพี (ประเทศไทย) จำกัด (มหาชน)
JSP PHARMACEUTICAL MANUFACTURING (THAILAND) PUBLIC COMPANY LIMITED

No. JPCS-22/011

Date: 28 June 2022

Re: Establishment of innovation center and small-scale production facility of dietary supplements and cosmetics
To Director and manager, The Stock Exchange of Thailand

JSP Pharmaceutical Manufacturing (Thailand) PCL. (“the Company”) would like to inform the resolution of the Board of Directors meeting no. 4/2022 on 28 June 2022, which significant resolution was approval of establishing innovation center and small-scale production facility of dietary supplements and cosmetics at Lam Luk Ka District, Pathum Thani Province. The project value was approximately Baht 65.0 million.

The Company is still emphasis in developing innovation products. Establishing innovation center will develop dietary supplements and cosmetics based on research papers which entrepreneurs could use such innovation to commercialise by producing in small-scale for market trial. The establishment of small-scale production facility of dietary supplements and cosmetics will produce under GMP standard to support entrepreneurs who use innovation. Furthermore, the Company will have more products offered to various group of customers, especially small entrepreneurs. Because the Company foresees high potential growth in this market from changing of consumer's behaviour by purchasing product from small entrepreneurs via online channel, this project will focus on small-batch production to persuade small entrepreneurs and provide access to the Company's products conveniently. The project will be operated by Caresutic Co., Ltd., which is the Company's subsidiary with direct shareholding of 99.99%, and will be operated commercially during the first quarter of 2023.

Moreover, the project's source of finance will derive from IPO proceed, which the Company can perform further process if and only if the Company obtains approval from the Extraordinary General Meeting no. 1/2565 on 16 August 2022 to change the objectives of IPO fund usage. However, the Company will plan to use working capital or borrowing from financial institution to continue this project if the Shareholder meeting disapproves such agenda.

To compute transaction size, the Company used financial information presented in the Company's interim financial information as of 31 March 2022. The highest transaction size was 5.39% based on total value of consideration. In connection with acquisition of assets in the last six months, the highest transaction size was 11.15% based on total value of consideration. In conclusion, this transaction is not required to execute under



บริษัท โรงงานเภสัชอุตสาหกรรม เจเอสพี (ประเทศไทย) จำกัด (มหาชน)
JSP PHARMACEUTICAL MANUFACTURING (THAILAND) PUBLIC COMPANY LIMITED

the Notification of the Capital Market Supervisory Board No. Tor Chor 20/2551 and is not a connected transaction.

Please be informed accordingly.

Sincerely yours,

JSP Pharmaceutical Manufacturing (Thailand) PCL.

Mr. Kiangkrai Rungruangthaweekul
Vice President of Finance

Investor Relations

Tel. 064 479 1691

Email ir@jsppharma.com